See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Trade War
Donald Trump
Social Media
Artificial Intelligence
Trade
Stock Markets
Natural Disasters
Baseball
European Union
Education
Taxes
Published • loading... • Updated

NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma

Summary by Science Daily
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study.

5 Articles

All
Left
Center
2
Right
Science DailyScience Daily
Center

NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study.

·United States
Read Full Article
Medical XpressMedical Xpress
Center

NK cells with bispecific antibody yield high response rates in patients with lymphoma: Clinical trial

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

Read Full Article
onclive.comonclive.com

NK Cells Complexed With Bispecific Antibody Yield High Response Rates in Patients With Lymphoma

A phase 1 trial demonstrated that AFM13-NK cells are safe and highly effective in heavily pretreated patients with lymphomas.

Read Full Article
BIOENGINEER.ORGBIOENGINEER.ORG

Bispecific Antibody-Complexed NK Cells Show Promising Response Rates in

Innovative Cell Therapy Offers Hope for Refractory CD30-Positive Lymphoma Patients A groundbreaking study has unveiled a novel cell therapy strategy that employs cord blood-derived natural killer (NK) cells pre-complexed with AFM13, a bispecific antibody targeting both CD30 and CD16A. This innovative approach shows promising safety profiles and high response rates in patients suffering from refractory CD30-positive lymphomas, particularly high-r…

Read Full Article
NewswiseNewswise

NK Cells Complexed with Bispecific Antibody Yield High Response Rates in Patients with Lymphoma

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

·Charlottesville, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Newswise broke the news in Charlottesville, United States on Friday, April 4, 2025.
Sources are mostly out of (0)

Similar News Topics

Science

Science

Medical

Medical

Houston, Texas

Houston, Texas

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal